Search
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541] … with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022.
Mifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalIts inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. … The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
Categories: Sex Hormones and Modulators of the Genital SystemViomycin
go.drugbank.com/drugs/DB06827ApprovedThese drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_.
Categories: Drugs for Treatment of TuberculosisCarbimazole
go.drugbank.com/drugs/DB00389ApprovedAn imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.
DCFBC F-18
go.drugbank.com/drugs/DB14772InvestigationalDCFBC F-18 is under investigation in clinical trial NCT02190279 (18F-DCFBC PET/CT in Prostate Cancer).
Human Rho(D) immune globulin
go.drugbank.com/drugs/DB11597ApprovedHuman Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). … Rho (D) immune globulin is available as a sterile, lyophilized or liquid gamma globulin (IgG) fraction containing antibodies to the Rh0 (D) antigen (D antigen) under the name Rhophylac (IM/IV).
Categories: anti-D (rh) immunoglobulinSynonyms: IGG, Rho (D), Anti-D immunoglobulinBenralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigationalBenralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils … [A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction.
Products: Fasenra 30 mg solution for injection in pre-filled syringe, Fasenra 30mg Solution for Injection in Pre-filled PenTebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigational[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.
Lymecycline
go.drugbank.com/drugs/DB00256ApprovedInvestigationalWithdrawnLymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. … [A203255] Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries.
Categories: combinations of tetracyclinesSynonyms: N-Lysinomethyltetracycline, (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamideSirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A13448] Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and … [L39292] In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular
Categories: Mammalian target of rapamycin (mTOR) kinase inhibitors